News
Yale Offers New Medication for Fatal Disease
Yale Medicine physicians were the first in Connecticut to offer a new medication for hereditary transthyretin-mediated amyloidosis (hATTR), a life-threatening genetic mutation that causes transport proteins called transthyretin to cluster together and deposit amyloids in the peripheral nerves, heart, kidney, and gastrointestinal tract.